Save up -80% on Varenicline
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Chantix
|$406.56||1 box (53 tablets)/starting month|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Chantix coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Varenicline every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Varenicline volume of distribution
|Champix||Tablet, film coated||0.5 mg||Oral||Pfizer|
|Champix||Tablet, film coated||1.0 mg||Oral||Pfizer|
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Varenicline
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc’s quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced.
Varenicline mechanism of action
Varenicline is an alpha-4 beta-2 neuronal nicotinic acetylcholine receptor partial agonist. The drug shows high selectiviyty for this receptor subclass, relative to other nicotinic receptors (500-fold alpha-3 beta-4, 3500-fold alpha-7, 20,000-fold alpha-1 beta gamma delta) or non-nicotinic receptors and transporters (2000-fold). The drug competitively inhibits the ability of nicotine to bind to and activate the alpha-4 beta-2 receptor. The drug exerts mild agonistic activity at this site, though at a level much lower than nicotine; it is presumed that this activation eases withdrawal symptoms.
Dosage forms of Varenicline
|Chantix Continuing Month Pak 56 1 mg tablet Disp Pack||$148.5||disp|
|Chantix Starting Month Pak 0.5 mg X 11, 1 mg X 42 Disp Pack||$148.5||disp|
|Chantix 1 mg tablet||$2.61||tablet|
|Chantix 0.5 mg tablet||$2.56||tablet|
|Chantix 1 mg cont month pak||$2.56||each|
Pfizer Canada Inc
Humans and other mammals
Indication of Varenicline
For use as an aid in smoking cessation.
Toxicity of Varenicline
Safety and efficacy of varenicline as an adjunct for smoking cessation have been established in 6 placebo-controlled or active-comparator studies in 3659 patients (mean age: 43 years; 79-96% white; mean smoking history: about 25 years) who smoked at least 10 cigarettes daily (mean: about 21 cigarettes daily). Safety and efficacy of varenicline also have been evaluated in a randomized, double-blind, placebo-controlled study in 703 patients with stable, documented cardiovascular disease (other than hypertension) who smoked at least 10 cigarettes daily; patients receiving varenicline and placebo were comparable in baseline characteristics, including age (mean age 57 and 55.9 years, respectively), race (80.3 and 80.8% white, respectively), gender (75.2 and 82.2% male, respectively), and mean smoking history (40 and 39 years, and 22.1 and 22.9 cigarettes daily, respectively). Safety and efficacy of varenicline also have been evaluated in a randomized, double-blind, placebo-controlled study in 460 patients (mean age 57 years, 82-84% white, approximately 62% male, mean smoking history of approximately 40 years) with mild to moderate chronic obstructive pulmonary disease (postbronchodilator FEV1/FVC below 70% and FEV1 at least 50% of predicted normal value) who smoked at least 10 cigarettes daily. Serious neuropsychiatric symptoms, including changes in mood (e.g., depression, mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, panic, and suicidality (e.g., suicidal ideation, attempted and completed suicides), have been reported during postmarketing experience in patients receiving varenicline. Hypersensitivity reactions, including angioedema, have been reported during postmarketing experience in patients receiving varenicline. Safety and efficacy of varenicline have not been established in patients younger than 18 years of age and use of the drug in this age group is not recommended. Varenicline was not genotoxic, with or without metabolic activation in vitro in human lymphocytes.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Varenicline on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
Get lower price on Varenicline now!
What is a Chantix?
Chantix is a cessation medication. It is used along with behavior modification and counseling support to help you stop smoking.
Chantix may cause changes in your thoughts or behavior. Stop using this medicine and consult a doctor immediately if you have: any change in mood or behavior, confusion, anxiety, panic attacks, hallucinations, extreme fear or if you feel impulsive, agitated, aggressive, anxious, hostile, depressed, hyperactive (Mentally or physically), or think about suicide or hurt yourself.
Do not drink large amounts of alcohol. Varenicline may increase the effect of alcohol or change the way it reacts.